Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 45 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 17 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Recurrence 8 Pancreatic Neoplasms 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

Cyclophosphamide 297 Rituximab 272 Etoposide 149 Filgrastim 142 fludarabine phosphate 120 Cytarabine 109 Vincristine 107 Melphalan 102 Radiotherapy 101 Doxorubicin 97 Peripheral Blood Stem Cell Transplantation 93 Methotrexate 91 fludarabine 86 Prednisone 86 Busulfan 86 Tacrolimus 66 Mycophenolic Acid 62 Granulocyte Colony-Stimulating Factor 60 Antilymphocyte Serum 58 Dexamethasone 57 Whole-Body Irradiation 55 Carmustine 54 Bortezomib 45 Cyclosporine 44 Lenalidomide 41 Methylprednisolone 40 sargramostim 39 Bendamustine Hydrochloride 37 ibritumomab tiuxetan 34 Ifosfamide 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × olaparib × Clear all

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

University of Texas Southwestern Medical Center

Phase 1 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡